Brief: Knight Therapeutics Announces Approval Of Additional Indication For Minjuvi® (Tafasitamab) In Brazil
17/03/2026 11:41
March 17 (Reuters) - Knight Therapeutics Inc GUD.TO: KNIGHT THERAPEUTICS ANNOUNCES APPROVAL OF ADDITIONAL INDICATION FOR MINJUVI® (TAFASITAMAB) IN BRAZIL Source text: ID:nGNX2DMdWK Further company coverage: GUD.TO ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Knight Therapeutics
See all newsBrief: Knight Therapeutics Announces Regulatory Approval Of Niktimvo In Brazil
Brief: Knight Therapeutics - Launches Tavalisse In Brazil For Chronic Immune Thrombocytopenia
Brief: Knight Therapeutics Enters Into Exclusive Distribution Agreement With Kyowa Kirin International For Poteligeo® (Mogamulizumab)
Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Colombia
Brief: Knight Therapeutics Announces Supplemental Regulatory Submission For Minjuvi In Brazil